The medical community continues to warn the public of the desperate need for new antibiotics to control infectious diseases. All too frequently, patients die of infections that current antibiotics are unable to control. The Infectious Disease Society of America is challenging the scientific community, policy makers and regulatory agencies to work together to “create a sustainable antibiotic R&D infrastructure” to identify ten new systemic antibiotics by 2020. How difficult will this be? What are the key hurdles? What efforts are on-going to speed the process of discovering and developing new antibiotics, and will any of these changes impact the discovery and development of drugs in other therapeutic areas? Join our speaker, Molly Schmid in a discussion that crosses science with policy!
What You Will Learn
- Understanding of the unique challenges in the discovery of new antimicrobials
- Appreciation for the evolutionary flexibility of microbes
- Understanding of important clinical needs for new antimicrobials
- Overview of recent scientific approaches, regulatory and policy changes that may impact the search for new antimicrobials
- And much more…
Date: Thursday, October 13, 2011
Time: 2:00-3:00 pm ET
Meet Your Expert
Molly B. Schmid, Ph.D. is Professor and Entrepreneur-in-Residence at Keck Graduate Institute of Applied Life Sciences in Claremont CA, where she teaches drug discovery and entrepreneurship. Prior to KGI, she was Senior Vice President of Preclinical Programs at Affinium Pharmaceuticals in Toronto, held leadership positions at Genencor International and Microcide Pharmaceuticals, and was an Assistant Professor of Molecular Biology at Princeton University. She is a Fellow of the American Academy of Microbiology. Dr. Schmid earned her PhD in biology from the University of Utah and her undergraduate degree in biology from SUNY Albany.
Meet the Moderator
B. Joseph Guglielmo, Pharm.D. is Professor and Chair in the Department of Clinical Pharmacy, School of Pharmacy at the University of California San Francisco. He also serves as Associate Director of Pharmaceutical Services at the UCSF Medical Center. Prior to his chairship, he was Vice Chair of Scholarship for the Department. His primary research interests involve the safe, effective, and appropriate use of antimicrobials, as well as the pharmacoepidemiology and pharmacokinetics of anti-infective agents. Dr. Guglielmo developed the Medical Center Antimicrobial Management Program in the 1980s and has mentored infectious diseases specialty residents and fellows continuously since 1986. He serves as long-term editor of Applied Therapeutics: The Clinical Use of Drugs and the Handbook for Applied Therapeutics.
The Fine Print
ACS Webinars™ does not endorse any products or services. The views expressed in this presentation are those of the presenters and do not necessarily reflect the views or policies of the American Chemical Society.